Financhill
Sell
27

GCTK Quote, Financials, Valuation and Earnings

Last price:
$4.17
Seasonality move :
-7.61%
Day range:
$4.17 - $4.47
52-week range:
$4.17 - $467.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.72x
P/B ratio:
43.73x
Volume:
12.4K
Avg. volume:
50.6K
1-year change:
-98.67%
Market cap:
$120.3M
Revenue:
--
EPS (TTM):
-$1,319.98

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, GlucoTrack, Inc. has -- downside to fair value with a price target of -- per share.

GCTK vs. S&P 500

  • Over the past 5 trading days, GlucoTrack, Inc. has underperformed the S&P 500 by -11.49% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • GlucoTrack, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • GlucoTrack, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter GlucoTrack, Inc. reported revenues of --.

Earnings Growth

  • GlucoTrack, Inc. earnings have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter GlucoTrack, Inc. reported earnings per share of -$4.64.
Enterprise value:
115.7M
EV / Invested capital:
--
Price / LTM sales:
6.72x
EV / EBIT:
--
EV / Revenue:
750.44x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-7.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$42K
Return On Assets:
-370.72%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
-2079.63%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -$25K -$22K -$42K -$10K -$9K
Operating Income -$6M -$13.1M -$16.5M -$3.3M -$4.3M
EBITDA -$5.9M -$13.1M -$16.4M -$3.2M -$4.3M
Diluted EPS -$1.59 -$2.89 -$1,319.98 -$0.91 -$4.64
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $7.4M $3.4M $7.2M $642K $8.1M
Total Assets $7.6M $3.5M $7.2M $826K $8.3M
Current Liabilities $898K $965K $1.5M $4.6M $5.3M
Total Liabilities $1.1M $1.2M $1.6M $4.8M $5.5M
Total Equity $6.5M $2.3M $5.6M -$4M $2.8M
Total Debt $234K $191K $184K $237K $239K
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$5.1M -$11.4M -$14.8M -$4.1M -$4.6M
Cash From Investing $5K -$104K -$76K -$33K -$67K
Cash From Financing $8.7M $5M $22.3M $4.4M $3M
Free Cash Flow -$5.1M -$11.5M -$14.9M -$4.2M -$4.7M
GCTK
Sector
Market Cap
$120.3M
$28.2M
Price % of 52-Week High
0.9%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-10.83%
-1.54%
1-Year Price Total Return
-98.67%
-18.1%
Beta (5-Year)
0.300
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $4.72
200-day SMA
Sell
Level $7.76
Bollinger Bands (100)
Sell
Level 4.9 - 7.02
Chaikin Money Flow
Sell
Level -53.7M
20-day SMA
Sell
Level $5.49
Relative Strength Index (RSI14)
Sell
Level 31.96
ADX Line
Sell
Level 15.49
Williams %R
Buy
Level -98.8189
50-day SMA
Sell
Level $5.79
MACD (12, 26)
Sell
Level -0.38
25-day Aroon Oscillator
Sell
Level -76
On Balance Volume
Neutral
Level 123.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-27.2139)
Sell
CA Score (Annual)
Level (-19.0174)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (29.62)
--
Piotroski F Score (Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

Stock Forecast FAQ

In the current month, GCTK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GCTK average analyst price target in the past 3 months is --.

  • Where Will GlucoTrack, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that GlucoTrack, Inc. share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About GlucoTrack, Inc.?

    Analysts are divided on their view about GlucoTrack, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GlucoTrack, Inc. is a Sell and believe this share price will rise from its current level to --.

  • What Is GlucoTrack, Inc.'s Price Target?

    The price target for GlucoTrack, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is GCTK A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for GlucoTrack, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of GCTK?

    You can purchase shares of GlucoTrack, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GlucoTrack, Inc. shares.

  • What Is The GlucoTrack, Inc. Share Price Today?

    GlucoTrack, Inc. was last trading at $4.17 per share. This represents the most recent stock quote for GlucoTrack, Inc.. Yesterday, GlucoTrack, Inc. closed at $4.20 per share.

  • How To Buy GlucoTrack, Inc. Stock Online?

    In order to purchase GlucoTrack, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 27

Galecto, Inc. [GLTO] is up 16.92% over the past day.

Sell
20
SMX alert for Dec 27

SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.

Sell
11
CDNAF alert for Dec 27

Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock